EMCURE - Swing Trade Analysis with AI Signals

Last Updated Time : 19 Sept 25, 2:15 pm

Swing Trade Rating: 3.4

📊 Technical & Momentum Overview

✅ Strengths

Price Action: Trading above 200 DMA (₹1,296), but slightly below 50 DMA (₹1,373)—trend is stabilizing.

EPS (₹21.1) vs Industry PE (33.4): Valuation is high, but earnings base is solid.

ROCE (13.5%) & ROE (11.6%): Moderate capital efficiency.

Debt-to-Equity (0.28): Reasonable leverage—adds margin of safety.

Qtr Profit Var (+210%): Strong YoY earnings momentum.

⚠️ Weaknesses

MACD (–16.2): Bearish divergence—momentum fading.

RSI (39.8): Bearish-neutral zone, indicating lack of strength.

Volume Drop: Current volume ~20% below 1-week average—weak participation.

FII & DII Outflows: –0.20% and –0.60%—institutional sentiment softening.

PAT Decline: ₹125 Cr vs ₹140 Cr—sequential earnings contraction.

PEG (–4.69): Negative PEG suggests unreliable growth valuation.

52W Index (70.6%)): Mid-range performance—no breakout confirmation.

According to ETMoney’s technical dashboard, EMCURE is showing mixed signals with support near ₹1,296 and resistance around ₹1,540. Analysts on TradingView suggest cautious optimism for long-term growth, but short-term momentum remains weak.

🎯 Optimal Entry Price

Buy Zone: ₹1,310–₹1,325 (near VWAP and 200 DMA)

Momentum Entry: ₹1,355–₹1,365 only if RSI crosses 45 and MACD flattens

🚪 Exit Strategy (If Already Holding)

Target Exit: ₹1,495–₹1,525 (near resistance and 52W high zone)

Stop Loss: ₹1,275 (below 200 DMA and recent support)

Exit Trigger: RSI dips below 38 or MACD diverges further

Selva, EMCURE is a technically cautious swing candidate with moderate fundamentals and recent earnings volatility. If you're building a pharma basket or want alert logic for MACD reversal and RSI breakout, I can help you script it.

Edit in a page